Restrain out the companies making headlines after the bell on Wednesday:
Shares of CRISPR Correctives plunged 18.5 percent in extended trading. The biotechnology company peached that the FDA has placed a clinical hold on its drug application for a sickle chamber disease stem cell therapy. The suspension will be in effect until CRISPR and Crest Pharmaceuticals answer FDA questions about the drug application.
Vertex slices crept down 0.4 percent after the announcement.
Box stock rolled 6.5 percent in the extended session, before recovering some of its impairments. The cloud storage company reported first quarter financial consequences that surpassed analyst expectations on top and bottom lines. Box reported reduction per share of 7 cents on revenue of $141 million. The street was expecting a injury of 8 cents on $140 million.
Box shares have gained 31 percent year-to-date.
Interests of Guess fell as much as 2 percent after the bell, before recovering some forfeitures. The clothing brand and retailer reported a 23 cent loss per parcel in the first quarter, which fell in-line with analyst outlooks. Guess surpassed Wall Street projections on revenue, reporting $521 million versus the $508 million awaited. The fashion brand issued weaker than anticipated earnings attitude for the second quarter and full year outlook.
Cars.com stock advanced 8 percent, before losing some of its gains in after hours buying. The classified auto listings site announced it had hired J.P. Morgan to study a possible sale.
PVH shares wobbled in extended trading and turned negating. The clothing company, which owns brands, like Tommy Hilfiger and Calvin Klein, fustigate analyst expectations on first quarter earnings and revenue and issued dazzling second quarter and full-year guidance. The apparel manufacturer has demonstrated stronger crop in international markets, like Europe and Asia, than in North America.
Interests of Symantec edged down nearly 1 percent in after hours business. The cybersecurity company, which owns Norton products, announced it would up on filing its annual shareholder report, related to an internal accounting poke into announced earlier in May. The company informed shareholders it did not think the probe last will and testament have a material impact on its past financial statements.